10x Genomics
TXG · NasdaqLaboratory Analytical Instruments · Fiscal year ends Dec 31
10x Genomics reported revenue of $643M in the fiscal year ended Dec 2025, up 5.2% from the year before. Operating income was −$61M, an operating margin of −9.5%, and net income was −$44M. Operating cash flow of $136M less capital expenditure of $6M left free cash flow of $130M.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | $490M | $516M | $619M | $611M | $643M |
| Cost of revenue | $74M | $120M | $209M | $196M | $199M |
| Gross profit | $416M | $396M | $409M | $414M | $444M |
| Selling, general & admin | $258M | $298M | $343M | $344M | $316M |
| Operating income | −$52M | −$168M | −$265M | −$195M | −$61M |
| Interest expense | $866,000 | $476,000 | $33,000 | $4,000 | $0 |
| Pre-tax income | −$54M | −$162M | −$249M | −$178M | −$40M |
| Income tax | $5M | $4M | $6M | $5M | $4M |
| Net income | −$58M | −$166M | −$255M | −$183M | −$44M |
| Diluted EPS | −0.53 | −1.46 | −2.18 | −1.52 | −0.35 |
| Diluted shares | 110M | 114M | 117M | 120M | 125M |
Balance sheet
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $587M | $220M | $359M | $344M | $474M |
| Receivables | $85M | $104M | $115M | $88M | $47M |
| Inventory | $60M | $82M | $74M | $83M | $56M |
| Current assets | $748M | $635M | $596M | $584M | $684M |
| Net PP&E | $169M | $289M | $280M | $253M | $227M |
| Goodwill | $5M | $5M | $5M | $5M | $5M |
| Total assets | $1B | $1B | $965M | $919M | $1B |
| Payables | $17M | $22M | $16M | $13M | $13M |
| Deferred revenue | $5M | $8M | $13M | $21M | $24M |
| Current liabilities | $110M | $131M | $127M | $118M | $153M |
| Total liabilities | $201M | $223M | $224M | $209M | $245M |
| Shareholders' equity | $818M | $806M | $741M | $710M | $796M |
| Backlog (remaining obligations) | $8M | $11M | $22M | $33M | $34M |
Cash flow
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −$21M | −$34M | −$15M | $7M | $136M |
| Capital expenditure | $101M | $132M | $49M | $12M | $6M |
| Free cash flow | −$123M | −$165M | −$64M | −$6M | $130M |
| Depreciation & amortisation | $21M | $25M | $36M | $36M | $36M |
| Stock-based compensation | $96M | $137M | $167M | $141M | $109M |
| Acquisitions | $5M | $4M | $0 | $0 | – |
Key ratios
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 5.3% | 19.8% | −1.3% | 5.2% |
| Gross margin | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% |
| Operating margin | −10.7% | −32.5% | −42.9% | −31.9% | −9.5% |
| Net margin | −11.9% | −32.1% | −41.2% | −29.9% | −6.8% |
| Return on equityBlank when equity is negative | −7.1% | −20.6% | −34.4% | −25.7% | −5.5% |
| ROCEEBIT ÷ (assets − current liabilities) | −5.8% | −18.7% | −31.7% | −24.3% | −6.9% |
| Free cash flow margin | −25.0% | −32.0% | −10.3% | −0.9% | 20.2% |
| Cash conversion (CFO ÷ net income) | 0.37x | 0.20x | 0.06x | −0.04x | −3.12x |
| Receivable days | 63 | 74 | 68 | 53 | 27 |
| Inventory days | 295 | 247 | 128 | 155 | 103 |
| Payable days | 85 | 65 | 27 | 24 | 23 |
| Interest cover | −60.3x | −353x | −8040x | −48640x | – |
| Current ratio | 6.77x | 4.85x | 4.69x | 4.97x | 4.46x |
Recent filings
More in Laboratory Analytical Instruments
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.